Bajaj Healthcare Ltd (BAJAJHCARE)

📊 Quarterly Results (₹ Cr)

The company has exhibited volatile profitability despite consistent top-line growth. Q1 FY26 revenue jumped 69.9% YoY to ₹16,644.31 lakhs, up from ₹153 lakhs in Q3 FY26 and ₹161 lakhs in Q4 FY25, indicating strong momentum. However, this growth was accompanied by a net loss of ₹1,369.80 lakhs, reversing prior profits, primarily due to exceptional items and reversal of revenue recognition. Operating margins remained stable at 13.1% in Q1 FY26, down slightly from 14.6% in Q4 FY25 but up from 9.8% in Q3 FY26, suggesting improving efficiency. Net profit had previously shown resilience, with ₹16 lakhs in Q4 FY25 and ₹11 lakhs in Q3 FY25, but the current loss reflects non-recurring financial and operational adjustments rather than fundamental deterioration.

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance in the latest filing, but in the context of the AGM notice and annual report, it emphasized a strategic transition toward higher-value segments like formulations and oncology, supported by export growth and continued investment in quality and regulatory compliance. The company highlighted the need for shareholder approval on key governance matters, including director reappointments beyond age 75 and remuneration adjustments, indicating long-term leadership continuity. The focus remains on sustainable expansion, regulatory adherence, and leveraging existing infrastructure to scale new therapeutic areas.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet shows a stable and improving capital structure, with total assets growing from ₹833 lakhs in March 2025 to ₹923 lakhs in March 2026, driven by asset base expansion. Equity and reserves have increased steadily, while borrowings rose marginally from ₹223 lakhs to ₹249 lakhs, indicating modest leverage growth. The debt-equity ratio improved to 0.47 as of March 2026 from 0.43 in the prior year, reflecting disciplined capital management. Despite net loss in Q1 FY26, the company retained sufficient equity buffers and maintained low leverage, supporting its strategy of funding growth through internal cash flows and selective borrowings.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Promoter holding has remained relatively stable around 58-59% over the past four quarters, indicating confidence in long-term prospects. Institutional ownership shows mixed trends: FII shareholding declined slightly from 1.12% in Q2 FY26 to 1.98% in Q4 FY26, while DII increased from 2.96% in Q3 FY26 to 2.91% in Q4 FY26, suggesting cautious accumulation. The number of shareholders has grown from 37,951 in Q3 FY26 to 41,310 in Q1 FY27, reflecting rising retail participation. No pledging or significant dilution was observed, and the shareholder base is broadening, which may support liquidity and governance scrutiny.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Profitability volatility due to non-recurring items and revenue reversals poses near-term earnings risk despite strong revenue growth. 2. Strategic transition from APIs to formulations and oncology introduces execution and market-entry risks in competitive therapeutic segments. 3. Regulatory and pricing pressures in domestic and export markets could impact margins and scalability. 4. Governance complexity may increase with proposed director reappointments beyond age 75 and higher remuneration, requiring shareholder approval and potentially affecting board dynamics.

📋 Recent Filings

• Announcement2026-09-23Bajaj Healthcare Ltd announced that its trading window will close on October 1, 2026, and remain shut for 48 hours after the release of un-audited qua…
• 🟡 voting results2026-09-22Bajaj Healthcare shareholders approved all six AGM resolutions via e-voting on September 21, 2026, including adoption of audited financials, final div…
• 🟡 Board Meeting2026-09-21Bajaj Healthcare held its 33rd AGM on September 21, 2026 via video conference, confirming quorum, adopting audited financials, declaring a ₹1.50 final…
• 🔴 Corporate Action2026-09-03Bajaj Healthcare announced a record date of September 14, 2026, for shareholders to determine entitlement to a proposed final dividend of 30% (₹1.50 p…
• 🟡 sustainability report2026-08-29Bajaj Healthcare Limited's BRSR report details its ESG performance for FY 2025-26, covering environmental stewardship, social initiatives, governance,…
• 🔴 annual report2026-08-29Bajaj Healthcare informed shareholders that the Annual Report 2025-26 is accessible via a web link for those who did not register their email addresse…
• 🟡 Board Meeting2026-08-29The 33rd Annual General Meeting of Bajaj Healthcare Ltd is scheduled for 21 September 2026 at 15:00 IST via video conferencing, with e-voting open fro…
• 🔴 annual report2026-08-29Bajaj Healthcare Limited announced its 33rd AGM scheduled for September 21, 2026, via video conferencing, and dispatched the FY 2025-26 Annual Report.…
• 🔴 Corporate Action2026-08-21Bajaj Healthcare announced the allotment of 2,500 equity shares of ₹5 face value each to a grantee upon exercise of vested stock options under its 202…
• Announcement2026-08-12Bajaj Healthcare announced DCGI approval to manufacture and market Cenobamate API and tablets across six strengths, marking its first CNS drug launch …

🧠 Analyst's Read

Bajaj Healthcare is executing a strategic shift toward higher-margin pharmaceutical segments, supported by growing export traction and operational scale, but near-term profitability remains pressured by non-recurring adjustments. Investors should monitor the outcome of AGM resolutions and the pace of formulation/oncology revenue contribution to assess the sustainability of the turnaround.

Based on filing content and financial data. Not a recommendation.